Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maria Matera and Paola Rogliani.
Maria Matera
Connection Strength
9.116
Paola Rogliani
  1. Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung. 2021 08; 199(4):335-343.
    View in: PubMed
    Score: 0.241
  2. Controversy surrounding the Sputnik V vaccine. Respir Med. 2021 10; 187:106569.
    View in: PubMed
    Score: 0.240
  3. Management of COPD patients during COVID: difficulties and experiences. Expert Rev Respir Med. 2021 08; 15(8):1025-1033.
    View in: PubMed
    Score: 0.237
  4. Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. Vaccines (Basel). 2021 Apr 01; 9(4).
    View in: PubMed
    Score: 0.234
  5. Disputes over the production and dissemination of misinformation in the time of COVID-19. Respir Med. 2021 06; 182:106380.
    View in: PubMed
    Score: 0.234
  6. Guidance on nebulization during the current COVID-19 pandemic. Respir Med. 2021 01; 176:106236.
    View in: PubMed
    Score: 0.229
  7. Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respir Med. 2020 09; 171:106114.
    View in: PubMed
    Score: 0.224
  8. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
    View in: PubMed
    Score: 0.210
  9. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opin Investig Drugs. 2019 Oct; 28(10):827-833.
    View in: PubMed
    Score: 0.210
  10. Pharmacological treatment and current controversies in COPD. F1000Res. 2019; 8.
    View in: PubMed
    Score: 0.210
  11. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019 07; 40(7):452-463.
    View in: PubMed
    Score: 0.206
  12. Monoclonal antibodies in severe asthma: is it worth it? Expert Opin Drug Metab Toxicol. 2019 Jun; 15(6):517-520.
    View in: PubMed
    Score: 0.206
  13. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019 05; 151:43-48.
    View in: PubMed
    Score: 0.204
  14. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2019 04; 20(6):737-750.
    View in: PubMed
    Score: 0.202
  15. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
    View in: PubMed
    Score: 0.200
  16. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opin Pharmacother. 2018 Dec; 19(18):2043-2053.
    View in: PubMed
    Score: 0.198
  17. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018 Oct; 14(10):1101-1111.
    View in: PubMed
    Score: 0.197
  18. Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. Eur J Pharmacol. 2018 Aug 05; 832:114-119.
    View in: PubMed
    Score: 0.192
  19. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opin Drug Saf. 2018 06; 17(6):589-596.
    View in: PubMed
    Score: 0.192
  20. Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? J Allergy Clin Immunol Pract. 2018 May - Jun; 6(3):1093-1094.
    View in: PubMed
    Score: 0.191
  21. Impact of doxofylline in COPD: A pairwise meta-analysis. Pulm Pharmacol Ther. 2018 08; 51:1-9.
    View in: PubMed
    Score: 0.191
  22. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomed Pharmacother. 2018 Jul; 103:1-8.
    View in: PubMed
    Score: 0.191
  23. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respir Res. 2018 04 12; 19(1):65.
    View in: PubMed
    Score: 0.191
  24. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulm Pharmacol Ther. 2018 06; 50:28-37.
    View in: PubMed
    Score: 0.190
  25. How does race/ethnicity influence pharmacological response to asthma therapies? Expert Opin Drug Metab Toxicol. 2018 Apr; 14(4):435-446.
    View in: PubMed
    Score: 0.190
  26. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin Drug Saf. 2018 Apr; 17(4):429-435.
    View in: PubMed
    Score: 0.190
  27. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018 05; 17(5):509-517.
    View in: PubMed
    Score: 0.190
  28. Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. Pulm Pharmacol Ther. 2018 04; 49:88-94.
    View in: PubMed
    Score: 0.188
  29. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulm Pharmacol Ther. 2018 04; 49:20-26.
    View in: PubMed
    Score: 0.187
  30. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018 Feb; 14(2):239-245.
    View in: PubMed
    Score: 0.187
  31. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulm Pharmacol Ther. 2018 02; 48:185-194.
    View in: PubMed
    Score: 0.186
  32. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Rev Respir Med. 2018 01; 12(1):43-54.
    View in: PubMed
    Score: 0.185
  33. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends Pharmacol Sci. 2017 10; 38(10):940-951.
    View in: PubMed
    Score: 0.182
  34. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD. 2017 Oct; 14(5):552-563.
    View in: PubMed
    Score: 0.182
  35. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD. 2017 Oct; 14(5):526-532.
    View in: PubMed
    Score: 0.182
  36. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Oct 05; 812:147-154.
    View in: PubMed
    Score: 0.181
  37. Adherence to COPD treatment: Myth and reality. Respir Med. 2017 08; 129:117-123.
    View in: PubMed
    Score: 0.180
  38. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Ther. 2017 08; 45:148-158.
    View in: PubMed
    Score: 0.180
  39. An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opin Pharmacother. 2017 Jul; 18(10):973-988.
    View in: PubMed
    Score: 0.179
  40. Bronchodilator therapy for chronic cough. Pulm Pharmacol Ther. 2017 Dec; 47:88-92.
    View in: PubMed
    Score: 0.179
  41. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May; 77(7):721-732.
    View in: PubMed
    Score: 0.179
  42. Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017 03; 11(3):239-253.
    View in: PubMed
    Score: 0.176
  43. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respir Res. 2017 01 24; 18(1):26.
    View in: PubMed
    Score: 0.175
  44. Optimizing drug delivery in COPD: The role of inhaler devices. Respir Med. 2017 03; 124:6-14.
    View in: PubMed
    Score: 0.175
  45. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017 Jan; 26(143).
    View in: PubMed
    Score: 0.175
  46. Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf. 2017 Jan; 8(1):17-30.
    View in: PubMed
    Score: 0.171
  47. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2018 08; 12(8):693-708.
    View in: PubMed
    Score: 0.049
  48. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Rev Respir Med. 2018 04; 12(4):261-264.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.